JNJ

225.91

+0.55%↑

UNH

362.52

-1.67%↓

TMO

465.38

+0.08%↑

ISRG

450.47

+0.05%↑

ABT

87.21

-0.76%↓

JNJ

225.91

+0.55%↑

UNH

362.52

-1.67%↓

TMO

465.38

+0.08%↑

ISRG

450.47

+0.05%↑

ABT

87.21

-0.76%↓

JNJ

225.91

+0.55%↑

UNH

362.52

-1.67%↓

TMO

465.38

+0.08%↑

ISRG

450.47

+0.05%↑

ABT

87.21

-0.76%↓

JNJ

225.91

+0.55%↑

UNH

362.52

-1.67%↓

TMO

465.38

+0.08%↑

ISRG

450.47

+0.05%↑

ABT

87.21

-0.76%↓

JNJ

225.91

+0.55%↑

UNH

362.52

-1.67%↓

TMO

465.38

+0.08%↑

ISRG

450.47

+0.05%↑

ABT

87.21

-0.76%↓

Inicio・Lista de Acciones・Erasca Inc

Search

Erasca Inc

Abierto

10 -6.37

Resumen

Variación precio

24h

Actual

Mínimo

9.93

Máximo

10.37

Métricas clave
By Trading Economics
Ingresos	1.5M -29M
Empleados	103
EBITDA	-2M -32M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+101.4% upside

Dividendos
By Dow Jones
Próximas Ganancias	11 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	1.1B 6B
Apertura anterior	16.37
Cierre anterior	10

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

1.39 / 1.44 Soporte y Resistencia

Erasca Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 may 2026, 22:17 UTC

Ganancias

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 may 2026, 23:47 UTC

Ganancias

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 may 2026, 23:45 UTC

Ganancias

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 may 2026, 23:45 UTC

Ganancias

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 may 2026, 23:40 UTC

Charlas de Mercado

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 may 2026, 22:44 UTC

Adquisiciones, fusiones, absorciones

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 may 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 may 2026, 22:42 UTC

Adquisiciones, fusiones, absorciones

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 may 2026, 22:42 UTC

Adquisiciones, fusiones, absorciones

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 may 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 may 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Shareholders to Own About 51% of Combined Company

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Board Unanimously Endorsed, Supported Deal

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Deal Unanimously Recommended by Vault Board

4 may 2026, 22:39 UTC

Adquisiciones, fusiones, absorciones

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 may 2026, 22:38 UTC

Adquisiciones, fusiones, absorciones

Regis Resources to Acquire All Ordinary Shares in Vault

4 may 2026, 22:38 UTC

Adquisiciones, fusiones, absorciones

Regis Resources, Vault Minerals Agree to Merger of Equals

4 may 2026, 22:37 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 may 2026, 22:26 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 may 2026, 22:02 UTC

Ganancias

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 may 2026, 22:00 UTC

Charlas de Mercado

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 may 2026, 21:52 UTC

Ganancias

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 may 2026, 21:50 UTC

Ganancias

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 may 2026, 21:50 UTC

Ganancias

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 may 2026, 21:49 UTC

Ganancias

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 may 2026, 21:44 UTC

Ganancias

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 may 2026, 21:44 UTC

Ganancias

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 may 2026, 21:43 UTC

Ganancias

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 may 2026, 21:41 UTC

Ganancias

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 may 2026, 21:40 UTC

Ganancias

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Comparación entre iguales

Cambio de precio

Erasca Inc previsión

Precio Objetivo

By TipRanks

101.4% repunte

Estimación a 12 Meses

Media 20.2 USD 101.4%

Máximo 30 USD

Mínimo 9 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

9

Comprar

1

Mantener

1

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Erasca Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.39 / 1.44Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Otras acciones del sector

JNJ

Johnson and Johnson

225.91

UNH

UnitedHealth Group Inc

362.52

TMO

Thermo Fisher Scientific Inc

465.38

ISRG

Intuitive Surgical Inc

450.47

ABT

Abbott Laboratories

87.21

Live chat